J Korean Soc Ther Radiol.  1995 Jun;13(2):149-156.

Postoperative adjuvant MVP Chemotherapy and Radiotherapy for Non-Small Cell Lung Cancer

• Kim JH
• Choi EK
• Chang HS
• Kim SW
• Suh CW
• Lee KH
• Lee JS
• Kim SH
• Kim WS
• Kim DS
• Kim WD
• Park SI
• Sohn KH

Abstract

PURPOSE: Since February 1991, a prospective study for non-small cell lung cancer patients who underwent radical resection and had a risk factor of positive resection margin or regional lymph node metastasis has been conducted to evaluated the effect of MVP chemotherapy and radiotherapy on the pattern of failure, disease free and oerall survival, and tolerance of combined treatment.
MATERIALS AND METHODS
Twenty nine patients were registered to this study until Sep. 1993 ; of these 26 received planned therapy. Within 3 weeks after radical resection, two cycles of MVP(Motomycin C 6 mg/m2 , Vinblastin 6 mg/m2 , Cisplatin 6 mg/m2 ) chemotherapy was given with 4 weeks intervals. Radiotherapy (5040 cGy tumor bed dose and 900 cGy boost to high risk area) was started 3 to 4 weeks after chemotherapy.
RESULTS
One and two year overall survival rates were 76.5% and 8.6% respectively. Locoregional failure developed in 6 patients (23.1%) and distant failure in 9 patients(34.6%). Number of involved lymph nodes, resection margin positivity showed some correlation with failure pattern but T-stage and N-stage showed no statistical significance. The group of paients who received chemotherapy within 2 weeks postoperatively and radiotherapy within 70 days showed lower incidence of distant metastasis. Postoperative combined therapy were well tolerated without definite increase of complication rate, and compliance rate in this study was 90%.
CONCLUSION
1) MVP chemotherapy showed no effect on locoregional recurrence, ut appeared to decrease the distant metastasis rate and 2) combined treatments were well tolerated in all patients. 3) he group of patients who received chemotherapy within 2wweks postoperatively and radiotherapy within 70 days showed lower incidence of distant metastasis. 4)Addition of chemotherapy to radiotherapy failed to increase the overall or disease free survival.

Keyword

Non-small cell Lung cancer; Postoperative chemotherapy; Postoperative radiotherapy

MeSH Terms

Carcinoma, Non-Small-Cell Lung*
Cisplatin
Compliance
Disease-Free Survival
Drug Therapy*
Humans
Incidence
Lymph Nodes
Neoplasm Metastasis
Prospective Studies
Radiotherapy*
Recurrence
Risk Factors
Survival Rate
Cisplatin